Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin holds $80,000 support as U.S. Treasury yields ease and Fed rate hike odds drop.

Market News
19 Oct 2026
Tokenpost
View Source
Neutral
Bitcoin holds $80,000 support as U.S. Treasury yields ease and Fed rate hike odds drop.

Bitcoin traded between $80,000 and $83,000 last week, maintaining $80,000 as a key support level amid pressure on tech stocks. The easing of U.S. Treasury yields and a drop in market expectations for a Federal Reserve rate hike in October to about 15% helped support Bitcoin's price. Institutional inflows into crypto remain unconfirmed, while market focus shifted from semiconductors to healthcare and banks. Bitcoin's implied volatility stayed below its one-year average, but a sustained move outside the $80,000 to $88,000 range could lead to significant price and volatility changes.

Bitcoin's recent trading between $80,000 and $83,000 is presented here alongside Pluang's market snapshot as of Oct 19, 2026 18:21 WIB: Among 50 major cryptocurrencies, 23 rose and 25 fell today. Notably, FTM (Fantom) declined by 2.05% to Rp11.382 with a typical hold time of 88 days, THETA (Theta Network) dropped 2.04% to Rp3.369 with 78 days typical hold time, while AXS (Axie Infinity) fell 1.83% to Rp18.020 but showed 100% buy order activity and a shorter hold time of 62 days.

More News

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics to host event on clinical measures in PKP2 arrhythmogenic cardiomyopathy

Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...

Others
Neutral
39 minutes ago
EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint's DURAVYU misses primary endpoint in wet AMD trial but shows reduced treatment burden and safety.

EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...

Company Fundamentals
Neutral
39 minutes ago
Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics wins $2.6M FDA grant to advance MT-601 therapy for pancreatic cancer.

Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...

Market News
Bullish
39 minutes ago
Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics appoints Mark Vale as audit committee chair ahead of public listing.

Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...

Company Fundamentals
Bullish
39 minutes ago
JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash wins Silver Award for innovation in InsurTech at Money20/20 USA 2026

JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...

Market News
Bullish
39 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App